Pelthos Therapeutics Inc. (PTHS)
NYSEAMERICAN: PTHS · Real-Time Price · USD
23.05
-0.07 (-0.30%)
Mar 9, 2026, 4:00 PM EDT - Market closed
Company Description
Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens.
The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older.
It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc. in July 2025.
Pelthos Therapeutics Inc. was founded in 2002 and is based in Durham, North Carolina.
Pelthos Therapeutics Inc.
| Country | United States |
| Founded | 2002 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 11 |
| CEO | Scott Plesha |
Contact Details
Address: 4020 Stirrup Creek Drive, Suite 110 Durham, North Carolina 27703 United States | |
| Phone | 877 265 8266 |
| Website | pelthos.com |
Stock Details
| Ticker Symbol | PTHS |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001919246 |
| ISIN Number | US1711262048 |
| Employer ID | 86-3335449 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Scott M. Plesha | Chief Executive Officer, President and Director |
| Francis Knuettel II, M.B.A. | Chief Financial Officer, Secretary and Treasurer |
| Sai Rangarao M.B.A. | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Feb 13, 2026 | 424B3 | Prospectus |
| Feb 9, 2026 | EFFECT | Notice of Effectiveness |
| Feb 5, 2026 | SCHEDULE 13G/A | Filing |
| Feb 2, 2026 | S-3 | Registration statement under Securities Act of 1933 |
| Jan 13, 2026 | 8-K | Current Report |
| Jan 12, 2026 | 8-K | Current Report |
| Jan 2, 2026 | 8-K | Current Report |
| Dec 23, 2025 | 8-K | Current Report |
| Dec 17, 2025 | 8-K | Current Report |